Ontology type: schema:ScholarlyArticle
2006-06-13
AUTHORSHei-Cheul Jeung, Sun Young Rha, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung
ABSTRACTPurposeThis study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients.MethodsPatients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50 mg/m2 followed by cisplatin 30 mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria.ResultsForty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9–39.3%) and disease control rate was 63.8% (95% CI, 50.9–79.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44 weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3–4 were rare with occurrence rate of 14.9% for anorexia and emesis.ConclusionsFractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes. More... »
PAGES313-320
http://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z
DOIhttp://dx.doi.org/10.1007/s00280-006-0272-z
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1014649059
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16770582
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adenocarcinoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Combined Chemotherapy Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Camptothecin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cisplatin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Irinotecan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Outpatients",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stomach Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Rate",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.15444.30",
"name": [
"Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Jeung",
"givenName": "Hei-Cheul",
"id": "sg:person.01276364570.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.15444.30",
"name": [
"Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea",
"BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Rha",
"givenName": "Sun Young",
"id": "sg:person.01036404665.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.15444.30",
"name": [
"Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea",
"BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Noh",
"givenName": "Sung Hoon",
"id": "sg:person.01120377020.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120377020.04"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.15444.30",
"name": [
"Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea",
"BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Roh",
"givenName": "Jae Kyung",
"id": "sg:person.0767622633.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea",
"id": "http://www.grid.ac/institutes/grid.15444.30",
"name": [
"Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea",
"BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea"
],
"type": "Organization"
},
"familyName": "Chung",
"givenName": "Hyun Cheol",
"id": "sg:person.016554426212.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s101470300007",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032208652",
"https://doi.org/10.1007/s101470300007"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1054/bjoc.2000.1631",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020520952",
"https://doi.org/10.1054/bjoc.2000.1631"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.bjc.6690350",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045469768",
"https://doi.org/10.1038/sj.bjc.6690350"
],
"type": "CreativeWork"
}
],
"datePublished": "2006-06-13",
"datePublishedReg": "2006-06-13",
"description": "PurposeThis study was to evaluate the activity and the safety of a combination chemotherapy regimen of weekly fractionated irinotecan and cisplatin in advanced gastric cancer patients.MethodsPatients with advanced gastric adenocarcinoma with either chemotherapy-naive or only one prior chemotherapy regimen received irinotecan 50\u00a0mg/m2 followed by cisplatin 30\u00a0mg/m2. Both drugs were administered weekly for 3 consecutive weeks, followed by 1-week rest. Treatment was repeated until disease progression occurred. Response evaluation was performed according to the RECIST criteria.ResultsForty-seven patients (13 chemo-naive, 34 prior chemotherapy) were enrolled. Of 46 evaluable patients, overall response rate was 25.5% (95% CI, 12.9\u201339.3%) and disease control rate was 63.8% (95% CI, 50.9\u201379.5%) by intent-to-treat analysis. The time to progression and overall survival duration were 21 and 44\u00a0weeks, respectively. One-year survival rate was 41.6%. The most frequent grade 4 toxicity was neutropenia, which was the major cause of treatment delay. Non-hematological toxicities of grade 3\u20134 were rare with occurrence rate of 14.9% for anorexia and emesis.ConclusionsFractionated irinotecan combined with cisplatin with 3-week-on and 1-week-off schedule produced favorable clinical results for advanced gastric cancer. Because of the feasible efficacy and low non-hematologic toxicity, this treatment could be a promising salvage regimen in patients who have failed to taxanes.",
"genre": "article",
"id": "sg:pub.10.1007/s00280-006-0272-z",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1088364",
"issn": [
"0344-5704",
"1432-0843"
],
"name": "Cancer Chemotherapy and Pharmacology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "59"
}
],
"keywords": [
"advanced gastric cancer",
"chemotherapy regimen",
"gastric cancer",
"one-year survival rate",
"advanced gastric cancer patients",
"prior chemotherapy regimen",
"disease control rate",
"grade 4 toxicity",
"non-hematologic toxicities",
"promising salvage regimen",
"overall survival duration",
"non-hematological toxicities",
"combination chemotherapy regimen",
"phase II trial",
"ResultsForty-seven patients",
"favorable clinical results",
"gastric cancer patients",
"overall response rate",
"advanced gastric adenocarcinoma",
"cisplatin 30",
"evaluable patients",
"salvage regimen",
"RECIST criteria",
"II trial",
"treat analysis",
"treatment delay",
"cancer patients",
"control rate",
"survival duration",
"gastric adenocarcinoma",
"disease progression",
"clinical results",
"feasible efficacy",
"grade 3",
"response rate",
"survival rate",
"patients",
"consecutive weeks",
"PurposeThis study",
"regimen",
"major cause",
"response evaluation",
"cisplatin",
"cancer",
"progression",
"weeks",
"toxicity",
"treatment",
"occurrence rate",
"MethodsPatients",
"neutropenia",
"emesis",
"adenocarcinoma",
"anorexia",
"irinotecan",
"taxanes",
"trials",
"drugs",
"efficacy",
"rate",
"m2",
"cause",
"duration",
"safety",
"rest",
"schedule",
"activity",
"criteria",
"evaluation",
"study",
"intent",
"delay",
"time",
"analysis",
"results"
],
"name": "A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer",
"pagination": "313-320",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1014649059"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00280-006-0272-z"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16770582"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00280-006-0272-z",
"https://app.dimensions.ai/details/publication/pub.1014649059"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:23",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_421.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00280-006-0272-z"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0272-z'
This table displays all metadata directly associated to this object as RDF triples.
244 TRIPLES
22 PREDICATES
120 URIs
109 LITERALS
23 BLANK NODES